anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to isolation by chromatography of (2R, 3R)-dihydroquercetin for production of biologically active supplements for medicine and pharmacy and food and cosmetics industry as well. The highly effective process for preparing (2R, 3R)-dihydroquercetin claimed enables to obtain the extremely pure product. The raw material containing dihydroquercetinis subjected to dissolution in aqueous ethanol solutionat 2-29 oC until the dihydroquercetin amount in solution of 50-250 g/l. Then the solution is subjected to chromatographic separation in a column under pressure 100-500 kg/cm2, the column being filled with reverse-phase sorbent. The sorbent is subjected to eluation with degassed modified ethyl alkohol aqueous solution. The portions of eluate are controlled by refractometry and mass spectrometry methods; then the product is subjected to crystallization, filtration and lyophylization. The product obtained contains at least 99,9 % of (2R,3R)-dihydroquercetin.
The gut microbiome is essential for maintaining organismal health. Gut microbiota may be disrupted through external factors like dietary change, which can lead to gut inflammation, resulting in obesity. Hibernating mammals develop low-grade gut inflammation when they accumulate fat deposits in preparation for hibernation, making them useful models for studying the relationship between the microbiome, inflammation, and weight gain. Nonsteroidal anti-inflammatory drugs and steroids are commonly used in humans to target gut inflammation, but how these drugs affect the gut microbiome and its stability is unclear. We investigated the effect of the glucocorticoid drug budesonide on the gut microbiome and cytokine levels of an obligate hibernator, the 13-lined ground squirrel, during the fattening season. We used 16S rRNA gene sequencing to characterize bacterial communities in the lumen and mucosa of the cecum and colon and measured proinflammatory [tumor necrosis factor-α (TNF-α)/interleukin 6 (IL-6)] and anti-inflammatory (IL-10) cytokine levels. Budesonide affected the microbiome only in the cecum lumen, where bacterial diversity was higher in the control group, and communities significantly differed between treatments. Across gut sections, Marvinbryantia and Enterococcus were significantly higher in the budesonide group, whereas Sarcina was higher in the control group. TNF-α and IL-6 levels were higher in control squirrels compared with the budesonide group, but there was no difference in IL-10 levels. Overall, budesonide treatment affected the microbial community and diversity of 13-lined ground squirrels in the cecum lumen. Our study presents another step toward developing ground squirrels as a model for studying the interaction between the microbiota and host inflammation.NEW & NOTEWORTHY Disruptions of gut microbiota can lead to inflammation, resulting in weight gain. Inflammation can be treated with budesonide, but how budesonide affects gut microbiota is unclear. Thirteen-lined ground squirrels experience low-grade gut inflammation during prehibernation fattening, which compares with human inflammation-weight gain mechanisms. We showed that budesonide treatment decreased microbiome diversity and lead to a shift in community in the cecum lumen. Our study supports developing ground squirrels as a model for studying microbiome-inflammation interactions.
INTRODUCTION/AIMS: Duchenne muscular dystrophy (DMD) is characterized by fibrofatty replacement of muscle. This has been documented in the ventricular myocardium of DMD patients, but there is limited description of atrial involvement. The purpose of this study is to examine the arrhythmia and ectopy burden in patients with DMD and non-DMD dilated cardiomyopathy (DCM) and to characterize the cardiac histopathologic changes in DMD patients across the disease spectrum.
METHODS: This was a retrospective analysis of age-matched patients with DMD and non-DMD DCM who received a Holter monitor and cardiac imaging within 100 days of each other between 2010 and 2020. Twenty-four-hour Holter monitors were classified based on the most recent left ventricular ejection fraction at the time of monitoring. Cardiac histopathologic specimens from whole-heart examinations at the time of autopsy from three DMD patients and one DCM patient were reviewed.
RESULTS: A total of 367 patients with 1299 Holter monitor recordings were included over the study period, with 94% representing DMD patients and 6% non-DMD DCM. Patients with DMD had more atrial ectopy across the cardiac function spectrum (p < 0.05). There was no difference in ventricular ectopy. Four DMD patients developed symptomatic atrial arrhythmias. Autopsy specimens from DMD patients demonstrated fibrofatty infiltration of both atrial and ventricular myocardium.
DISCUSSION: The atrial myocardium in patients with DMD is unique. Autopsy specimens reveal fibofatty replacement of the atrial myocardium, which may be a nidus for both ectopy and arrhythmias in DMD patients.
PURPOSE: A complex antibiotics composition is provided to suppress antibiotics resistant strain and to effectively prevent and treat complex infectious diseases. CONSTITUTION: A complex antibiotic composition for animal contains cefuroxim or amoxicillin and florfenicol in weight ratio of 0.3-3:1. The complex antibiotics is used in the form of injection, powder, or ointment. A complex antibiotics composition additionally contains pharmaceutically acceptable solvent or emulsifying agne as a animal injection. The solvent is glycerol formal, N-methyl-2-pyrrolidone or mixture thereof. The emulsifying agent is polyoxyethylene castor oil, polysorbate, propylene glycol dicarprylate/dicarprylate or mixture thereof.
AIMS: To establish a comprehensive understanding of the roles of midwives and the challenges they encounter in the prevention, diagnosis and management of postpartum haemorrhage (PPH) following normal vaginal delivery.
DESIGN: We conducted a scoping review following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis for Scoping Reviews (PRISMA-ScR) recommendations.
METHODS: We considered studies related to the roles of midwives and the challenges they encounter in the prevention, diagnosis and management of PPH during vaginal delivery. We excluded guidelines, consensuses, abstracts of meetings and non-English language studies. Databases, including the Cochrane Library, PubMed, Web of Science, Ovid, Medline, Embase, JBI EBP and BIOSIS Previews, were searched on January 1, 2023, with no time limitations.
RESULTS: We included 28 publications. Midwives play important roles in the prevention, diagnosis and management of postpartum haemorrhage during vaginal delivery. In the prevention of PPH, midwives' roles include identifying and managing high-risk factors, managing labour and implementing skin-to-skin contact. In the diagnosis of PPH, midwives' roles include early recognition and blood loss estimation. In the management of PPH, midwives are involved in mobilizing other professional team members, emergency management, investigating causes, enhancing uterine contractions, the repair of perineal tears, arranging transfers and preparation for surgical intervention. However, midwives face substantial challenges, including insufficient knowledge and skills, poor teamwork skills, insufficient resources and the need to deal with their negative emotions. Midwives must improve their knowledge, skills and teamwork abilities. Health care system managers and the government should give full support to midwives. Future research should focus on developing clinical practice guidelines for midwives for preventing, diagnosing and managing postpartum haemorrhage.
Lehfilcon A contact lenses worn first, with senofilcon A contact lenses worn second, as randomized. The lehfilcon A contact lenses will be worn for approximately 28 days. The senofilcon A contact lenses will be worn for approximately 14 days. Lenses will be worn bilaterally (in both eyes) in a daily wear modality, with AOSEPT PLUS with HydraGlyde used for nightly cleaning and disinfection.
This work will be a quasi-experimental study where we aim to test the feasibility and safety of walking football in patients with T2D. The recruitment of participants will be held in primary health care units by Family Medicine medical doctors. All participants will receive instructions to maintain daily-life routines (lifestyle-related physical activity and dietary pattern), and to continue with usual care (diabetes consultations on primary health care units and pharmacological regimen) along the studies duration. All participants will receive basic sports material (sports bag, T-shirt, and sports shoes). Participants will be organized in two teams of 20 players. Each team will have 60-min walking football exercise sessions three times per week (non-consecutive days), during three months (36 sessions). Different walking football exercise strategies will be developed according to participants' motor skills and tested with dose-escalated intensity for its safety (acute effects on capillary glycaemia, blood pressure, foot impact, exercise-related injuries and adverse events) and enjoyment. Exercise intensity will range between light to vigorous. No submaximal or maximal exercises will be tested. Cumulative short-term effects will also be analyzed along the three months through pre- and post-study evaluations. Exercise sessions will be conducted on a sports hall (indoor court) by a football coach and supervised by an exercise physiologist and a nurse.
Inhaled fluticasone furoate is absorbed into the circulation and can be systemically active. Effects of fluticasone furoate on the HPA axis are not observed with the therapeutic doses of fluticasone furoate in BREO ELLIPTA. However, exceeding the recommended dosage or coadministration with a strong cytochrome P450 3A4 (CYP3A4) inhibitor may result in HPA dysfunction [see Warnings and Precautions (5.9), Drug Interactions (7.1)].

Because of the possibility of significant systemic absorption of ICS in sensitive patients, patients treated with BREO ELLIPTA should be observed carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients postoperatively or during periods of stress for evidence of inadequate adrenal response.

It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients who are sensitive to these effects. If such effects occur, reduce the dose of BREO ELLIPTA slowly, consistent with accepted procedures for reducing systemic corticosteroids, and consider other treatments for management of COPD or asthma symptoms.
The utility model discloses a novel rheumatism analgesic ointment comprising a base cloth and an ointment layer spread on the surface of the base cloth. The surface of the ointment layer is covered by a plastic film. The novel rheumatism analgesic ointment is characterized in that the ointment layer comprises inner ring medicine with relatively weak stickiness and outer ring medicine with relative stronger stickiness. The base cloth is cut to an oval shape. The outer ring medicine is in an oval ring shape with a ring width less than 1 cm. The novel rheumatism analgesic ointment is easy to strip off after application on the surface of the skin and is not prone to curling in application.
Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily. At week 26, patients were re-randomised to receive 10 milligram (mg) empagliflozin, taken once daily, until end of treatment.
PURPOSE: To efficiently adsorb the metalloprotein in whey and to elute and extract the metalloprotein by coating the wall surfaces of inorg. porous particles to be adsorbed with the metalloprotein with the films of aminated polysaccharides having acidic functional groups on the surfaces. CONSTITUTION: At the time of extracting the metalloprotein and more particularly protein bonded with iron (lactophene, transferrin, lactoperoxidase, etc.,) in the whey, the whey is brought into contact with the inorg. porous particles of which the wall surfaces are coated with the films of the aminated polysaccharides having the acidic functional groups on the surfaces. As a result, the metalloprotein is adsorbed on the surface of the porous particles. The metalloprotein is thereafter eluted by an eluent. The polysaccharides are preferably dextran and more particularly preferably diethylaminoethyl dextran. The inorg. porous particles are preferably spherical silica having a diameter of 10 to 1000μm and have pores of an average diameter of 5 to 200nm.
FIELD: medicine. SUBSTANCE: method involves oral administration of preparation containing cesium ions, preferably as cesium chloride, and preferably with magnesium ions as magnesium sulfate. Surface application is proposed by preferable variant that involves the use of microporous material bands (A). Material has the layer (B) on the both side of its plastic base. Layer is impregnated with an aqueous solution containing cesium chloride and magnesium sulfate. Alternative variant has a preparation as cream which contains cesium chloride that is used for surface application on patient. EFFECT: improved method of treatment.
TOCT includes six different workstations in which subjects exercise for 5 minutes in each one (3 minutes of exercise and 2 minutes of rest). During each session, subjects undergo 2 laps that take about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary. This is a progressive circuit and subjects while exercising receive feedbacks (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One session includes up to 3 patients and lasts 120 minutes, 5 days/week for 2 weeks. After this period they will receive a home-exercise maintenance program for 3 months.
FIELD: medicine.SUBSTANCE: invention relates to medicine, specifically to surgical gynecology. Carry out the removal of myoma nodules from the abdominal cavity using morcellator. In this case, the surgeon is located to the right of the patient, sets the port for the laparoscope at the point of Hasson, located at the intersection of the middle mammary line and a point 3 cm below the left costal arch, and working ports for instruments: the central port – at the umbilical point, the left and right lateral ports – above typical McBurney points, due to their projection onto the horizontal through the umbilical point. Then, a two-stage hydropreparation is performed before the incision is made on the uterus with a solution consisting of norepinephrine 0.00001 %, Methylergobrevin 2.0 ml, 0.9 % physiological saline solution 100 ml. Next, a cut in the uterus is performed above the maximum diameter of the node in the longitudinal direction of the 1st muscular layer of the uterus and in the transverse direction of the 2nd muscular layer of the uterus along the main muscle fibers and their accompanying vessels, and enucleation of myoma nodes is performed using a harmonic ultrasonic scalpel. Then, the myometrium is sutured with separate endosutures in two layers using a monofilament suture which is made of Monocryl 0 with the largest needle size. In this case, the closure is performed with the left hand from the central and left side port. Suturing the inner layer, made in the transverse direction, is performed from top to bottom, perpendicular to the incision. And the closure of the outer layer of the myometrium is performed from left to right, perpendicular to the incision. Then an anti-adhesive membrane of polyoxidized starch is placed on the line of stitches on the uterus. Hysteroscopy is performed to exclude the suture penetration into the uterine cavity.EFFECT: method allows to improve the results of treatment, reduce blood loss, form a full-fledged scar on the uterus.1 cl, 14 dwg, 1 ex
Oral submucous fibrosis (OSF) is a precancerous condition in the oral cavity, which is closely related to the myofibroblast conversion of buccal mucosal fibroblasts (BMFs) after chronic consumption of areca nut. Emerging evidence suggests pyroptosis, a form of programmed cell death that is mediated by inflammasome, is implicated in persistent myofibroblast activation and fibrosis. Besides, numerous studies have demonstrated the effects of non-coding RNAs on pyroptosis and myofibroblast activities. Herein, we aimed to target key long non-coding RNA PVT1 with natural compound, carvacrol, to alleviate pyroptosis and myofibroblast activation in OSF. We first identified PVT1 was downregulated in the carvacrol-treated fBMFs and then demonstrated that myofibroblast features and expression of pyroptosis makers were all reduced in response to carvacrol treatment. Subsequently, we analysed the expression of PVT1 and found that PVT1 was aberrantly upregulated in OSF specimens and positively correlated with several fibrosis markers. After revealing the suppressive effects of carvacrol on myofibroblast characterisitcs and pyroptosis were mediated by repression of PVT1, we then explored the potential mechanisms. Our data showed that PVT1 may serve as a sponge of microRNA(miR)-20a to mitigate the myofibroblast activation and pyroptosis. Altogether, these findings indicated that the anti-fibrosis effects of carvacrol merit consideration and may be due to the attenuation of pyroptosis and myofibroblast activation by targeting the PVT1/miR-20a axis.
ZYPREXA RELPREVV may induce orthostatic hypotension associated with dizziness, tachycardia, bradycardia and, in some patients, syncope, probably reflecting its α1-adrenergic antagonistic properties [see Patient Counseling Information (17)]. Syncope-related adverse reactions were reported in 0.1% of patients treated with ZYPREXA RELPREVV in clinical studies. 

From an analysis of the vital sign data in an integrated database of 41 completed clinical studies in adult patients treated with oral olanzapine, orthostatic hypotension was recorded in ≥20% (1277/6030) of patients. 

Olanzapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. For patients in this population who have never taken oral olanzapine, tolerability should be established with oral olanzapine prior to initiating treatment with ZYPREXA RELPREVV [see Dosage and Administration (2.1)]. 

Caution is necessary in patients who receive treatment with other drugs having effects that can induce hypotension, bradycardia, respiratory or central nervous system depression [see Drug Interactions (7)].
Participation will be two years and it involves blood collection, collection of medical information and images from standard of care kidney biopsies. Subjects will be asked to complete questionnaires for the study at 12 and 24 months after kidney transplant. The research blood tests that are being collected for the study are called Trugraf® and Viracor® Trac. The principal investigator is using this test to see if they can predict and monitor rejection in our kidney transplant patients.

At the time of the 4 month standard of care kidney biopsy, if participants have not experienced any rejection episodes or formed any donor specific antibodies (dnDSA) and are still eligible, randomization will occur. Participants will be put into 1 of 2 groups: Mycophenolate Mofetil Maintenance group where the subject would continue on current medication, or the subject will be placed into the MMF Withdrawal group which means they would slowly be withdrawn from this medication. If the subject is not eligible to be randomized, they will remain in the study and placed into the Non-Randomized group and continue to have study related visits and procedures like the MMF Maintenance group.
Procedure for obtaining 1- (3-mercapto-2-methylpropandyl) -l-proline. Is to react l-prolin tero-butil ester with 3-acetyl tio-2-methyl propionic acid through the mixed anhydric obtained from the acid acetylide hetil-propionico and ethyl chloroformate. The group tero-butil ester and acetilo are hydrologed thereof. The rest acetile is hydrolysed with methanil/trietilamine in atmosphere inerte. The purification of the product is carried out through its salt with diciclohexilamin with posterior regeneration of the acid. Antihypertensive. 1 (Machine-translation by Google Translate, not legally binding)
INTRODUCTION: Postoperative laryngopharyngeal discomfort after extubation can lead to severe throat pain, dysphagia, or postoperative tongue oedema. Possible mechanisms include increased oral pressure, obstruction of venous and lymphatic return in the neck, and increased capillary hydrostatic pressure, which leads to oedema of the tongue and upper airway. However, real-time monitoring indicators of anaesthesia are lacking. Therefore, we designed this study to accurately measure the contact force of the tracheal tube on the tongue in different surgical positions during general anaesthesia.
METHODS AND ANALYSIS: This prospective single-centre observational study will enrol 54 patients undergoing elective surgery under general anaesthesia for>2 hours with endotracheal tube application from 1 July 2023 to 30 June 2024. Patients will be divided into the supine (Supine group) and high-risk (Flexion group) groups. Dynamic changes in the contact force between the tracheal tube and tongue will be measured using T-Scan technology. All patients will be followed up for 7 days postoperatively. The primary endpoint is postoperative laryngopharyngeal discomfort. Secondary outcomes include the time to the first successful recovery of oral intake of fluids and solid food, and airway-related events.
ETHICS AND DISSEMINATION: Ethical approval was obtained from the Ethics Committee of Clinical Research of China-Japan Friendship Hospital (2023-KY-219, approved on 14 September 2023). Informed consent will be obtained during anaesthesia evaluation. This study aims to explore the characteristics of the contact force on the tongue caused by endotracheal intubation in different surgical positions and to provide a better understanding of the risk factors and prevention of postoperative laryngopharyngeal discomfort. The findings of this study will be presented at our hospital, reported on ClinicalTrials.gov, and published in peer-reviewed journals.
TRIAL REGISTRATION NUMBER: NCT05987293.